Exploring “ADC + Antibody” as an Emerging Combination Strategy for Solid Tumor Therapies
- Explaining rationale for combining a HER2 ADC with trastuzumab
- Describing preclinical and clinical results of combination trials, highlighting clinical benefit of ADC antibody combinations
- Investigating mechanism to understand how antibody combination helps ADC overcome binding site barrier to improve tumor penetration and improve efficacy